Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients
نویسندگان
چکیده
ObjectivesAbiraterone acetate is registered for the treatment of metastatic castration-sensitive and resistant prostate cancer (mCRPC). Treatment outcome associated with plasma trough concentrations (Cmin) abiraterone. Patients a Cmin below target 8.4 ng/mL may benefit from optimization by dose increase or concomitant intake food. This study aims to investigate cost-effectiveness monitoring abiraterone in patients mCRPC.MethodsA Markov model was built health states progression-free survival, progressed disease, death. The benefits followed food intervention were modeled via difference percentage achieving adequate taking healthcare payer perspective. Deterministic probabilistic sensitivity analyses performed assess uncertainties their impac incremental ratio (ICER).ResultsMonitoring resulted 0.149 quality-adjusted life-years (QALYs) €22 145 costs an ICER €177 821/QALY. assumed equal effects estimated €7599, resulting €61 019/QALY. likelihoods therapeutic drug (TDM) being cost-effective 8.04%and 81.9%, respectively.ConclusionsMonitoring not mCRPC Monitoring combination likely be cost-effective. assessment assist decision making future integration TDM into standard practices patients.
منابع مشابه
Abiraterone acetate: in metastatic castration-resistant prostate cancer.
Oral abiraterone acetate, in combination with prednisone/prednisolone, is used to treat patients with metastatic castration-resistant prostate cancer (CRPC) who have previously received docetaxel-containing chemotherapy. Abiraterone acetate was developed to specifically inhibit cytochrome P450 (CYP)17A1, which is an essential enzyme in the biosynthesis of testosterone. In a pivotal phase III tr...
متن کاملAbiraterone acetate for metastatic castration-resistant prostate cancer post-docetaxel
Abiraterone acetate (AA) 1000-mg daily, a selective irreversible androgen biosynthesis inhibitor of cytochrome P450 c17 (CYP17) enzyme, is used in combination with prednisone 10-mg daily to treat docetaxel-treated patients with metastatic castration-resistant prostate cancer (mCRPC). Several studies have demonstrated the safety and efficacy of this compound in men with mCRPC. Interim results fr...
متن کاملClinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide.
BACKGROUND Abiraterone acetate and enzalutamide both improve outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC). Optimal sequencing for these agents and whether cross-resistance occurs is unknown. METHODS Multicentre review of patients with mCRPC treated with abiraterone acetate and prednisone after progressing on enzalutamide. Primary objective was to determine...
متن کاملFeasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation
BACKGROUND Abiraterone acetate (AA), a selective inhibitor of the CYP17 enzyme, demonstrated a significant improvement in the treatment of patients with metastatic castration-resistant prostate cancer. The risk of endocrine side effects, mainly an increased adrenal mineralocorticoid production, could limit its use in patients with atrial fibrillation. METHODS We retrospectively reviewed the c...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2021
ISSN: ['1098-3015', '1524-4733']
DOI: https://doi.org/10.1016/j.jval.2020.04.1838